Sagimet Biosciences Inc. - Seri (SGMT) Q2 2026 earnings — TrendMatrix coverage

Reported EPS

—

Estimate

-$0.27

Surprise

—

Score today

5.6/10

Revenue for this quarter isn’t shown: the reported figure hasn’t cleared TrendMatrix’s freshness and sanity checks yet, and consensus revenue isn’t tracked. EPS above is the available figure.

• Citizens Maintains Market Outperform on Sagimet Biosciences, Raises Price Target to $29 — benzinga, 2026-08-14
• Sagimet Biosciences Says FDA Cleared IND And Issued Study May Proceed Letter For Phase 3 Trial Of Denifanstat In Moderat — benzinga, 2026-08-13
• Canaccord Genuity Maintains Buy on Sagimet Biosciences, Raises Price Target to $56 — benzinga, 2026-08-12

TrendMatrix currently rates SGMT Sell at 5.6/10; no pre/post engine snapshot brackets this report.

3 of the last 4 quarters beat the estimate. Next scheduled report: 2026-11-12.

This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.

Current price

$10.25

Price target

$24.88

Stop

$9.53

Upside to target

+142.7%

Reward-to-risk

9.5:1

Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.

Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.

Industry

Biotechnology

Market cap

$637.1M

P/E (fwd)

-7.6

52-week range

$4.50–$11.15

Off 52-week high

8.1%

RSI (14)

83

Volume vs avg

0.78×

Score today

5.6/10